Stock Events

Merck KGAA 

€153.05
229
+€2.85+1.9% Today

Statistics

Day High
153.05
Day Low
153.05
52W High
-
52W Low
-
Volume
27
Avg. Volume
-
Mkt Cap
65.04B
P/E Ratio
23.99
Dividend Yield
1.42%
Dividend
2.17

Upcoming

Dividends

1.42%Dividend Yield
10Y Growth
4.1%
5Y Growth
11.01%
3Y Growth
11.71%
1Y Growth
-2.68%

Earnings

15MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
1.94
2.21
2.47
2.73
Expected EPS
2.0472166565031795
Actual EPS
2.243226761913059

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MRK.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.
Show more...
CEO
Ms. Belen Garijo Lopez M.D.
Employees
62345
Country
DE
ISIN
DE0006599905
WKN
000659990

Listings